Detailed information for compound 207809

Basic information

Technical information
  • TDR Targets ID: 207809
  • Name: ethyl 3-(acetyloxymethyl)-5-(aziridin-1-yl)-4 ,7-dioxo-1H-indole-2-carboxylate
  • MW: 332.308 | Formula: C16H16N2O6
  • H donors: 1 H acceptors: 4 LogP: 0.92 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCOC(=O)c1[nH]c2c(c1COC(=O)C)C(=O)C(=CC2=O)N1CC1
  • InChi: 1S/C16H16N2O6/c1-3-23-16(22)13-9(7-24-8(2)19)12-14(17-13)11(20)6-10(15(12)21)18-4-5-18/h6,17H,3-5,7H2,1-2H3
  • InChiKey: XQCBQICITWYCLC-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • ethyl 3-(acetoxymethyl)-5-(aziridin-1-yl)-4,7-dioxo-1H-indole-2-carboxylate
  • 3-(acetoxymethyl)-5-(1-aziridinyl)-4,7-dioxo-1H-indole-2-carboxylic acid ethyl ester
  • 3-(acetoxymethyl)-5-ethylenimino-4,7-diketo-1H-indole-2-carboxylic acid ethyl ester

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Brugia malayi ubiquitin conjugating enzyme protein 13 0.0235 1 1
Trichomonas vaginalis ubiquitin-conjugating enzyme E2, putative 0.0235 1 1
Trichomonas vaginalis ubiquitin-conjugating enzyme E2, putative 0.0235 1 1
Trypanosoma cruzi ubiquitin-conjugating enzyme E2, putative 0.0235 1 1
Entamoeba histolytica ubiquitin-conjugating enzyme family protein 0.0235 1 0.5
Mycobacterium leprae RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE (ALPHA CHAIN) NRDE (RIBONUCLEOTIDE REDUCTASE SMALL SUBUNIT) (R1F PROTEIN) 0.0083 0 0.5
Loa Loa (eye worm) ubiquitin conjugating enzyme protein 13 0.0235 1 1
Echinococcus multilocularis ubiquitin conjugating enzyme E2 N 0.0235 1 1
Chlamydia trachomatis ribonucleoside-diphosphate reductase subunit alpha 0.0098 0.1006 0.5
Trypanosoma brucei ubiquitin-protein ligase, putative 0.0235 1 1
Toxoplasma gondii ubiquitin-conjugating enzyme subfamily protein 0.0235 1 1
Plasmodium vivax ubiquitin-conjugating enzyme E2 N, putative 0.0235 1 1
Treponema pallidum ribonucleotide-diphosphate reductase subunit alpha 0.0098 0.1006 0.5
Wolbachia endosymbiont of Brugia malayi ribonucleotide-diphosphate reductase subunit alpha 0.0083 0 0.5
Plasmodium falciparum ubiquitin-conjugating enzyme E2 N, putative 0.0235 1 1
Loa Loa (eye worm) ubiquitin conjugating enzyme protein 13 0.0235 1 1
Mycobacterium ulcerans ribonucleotide-diphosphate reductase subunit alpha 0.0083 0 0.5
Leishmania major ubiquitin-conjugating enzyme e2, putative 0.0235 1 1
Trypanosoma cruzi ubiquitin-conjugating enzyme E2, putative 0.0235 1 1
Mycobacterium tuberculosis Ribonucleoside-diphosphate reductase (alpha chain) NrdE (ribonucleotide reductase small subunit) (R1F protein) 0.0083 0 0.5
Echinococcus granulosus ubiquitin conjugating enzyme E2 N 0.0235 1 1
Schistosoma mansoni ubiquitin conjugating enzyme 13 0.0235 1 1

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 91.2 % % of DNA reductive alkylation determined by catalytic reduction of aziridinyl quinones in presence of 600 bp calf thymus DNA ChEMBL. 11606119
Average log LC50 (functional) = -5.62 Cancer specificity was measured from the +/- value under average log LC50 60-cell line . ChEMBL. 11606119
GI50 (functional) = -7.43 Concentration of the drug required for 50% growth inhibition against NSC (non small cell) H460 cell line. ChEMBL. 11606119
Km (binding) = 0.00000459 M Apparent dissociation constant KM for human DT-diaphorase(from non-small-cell lung NCI-H460 cell line) ChEMBL. 11606119
Km (binding) = 45900 M Apparent dissociation constant KM for human DT-diaphorase(from non-small-cell lung NCI-H460 cell line) ChEMBL. 11606119
LC50 (functional) = -6.22 Concentration required for 50% cell kill. against NSC H460 cell line. ChEMBL. 11606119
LC50 (functional) = -5.619999999999997 Cancer specificity was measured from the +/- value under average log LC50 60-cell line . ChEMBL. 11606119
Log GI50 (functional) = 7.43 Concentration of the drug required for 50% growth inhibition against NSC (non small cell) H460 cell line. ChEMBL. 11606119
Log LC50 (functional) = 6.22 Concentration required for 50% cell kill. against NSC H460 cell line. ChEMBL. 11606119
Log TGI (functional) = 6.77 Concentration of the drug required for total growth inhibition against NSC H460 cell line. ChEMBL. 11606119
Ratio (binding) = 721800 The substrate specificity obtained from the ratio of Vmax to KM for human DT-diaphorase (from non-small-cell lung NCI-H460 cell line) ChEMBL. 11606119
TGI (functional) = -6.770000000000001 Concentration of the drug required for total growth inhibition against NSC H460 cell line. ChEMBL. 11606119
Vmax (binding) = 33130000000 M s-1 Apparent maximum velocity Vmax for human DT-diaphorase(from non-small-cell lung NCI-H460 cell line) ChEMBL. 11606119
Vmax (binding) = 33130000000 M s-1 Apparent maximum velocity Vmax for human DT-diaphorase(from non-small-cell lung NCI-H460 cell line) ChEMBL. 11606119

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.